$0.11
4.55%
Nasdaq, Wed, Oct 21 2026.
ISIN
US8006771062
Symbol
SGMO

Sangamo Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation

Sangamo Therapeutics, Inc. Classifications & Recommendation

Buy
73%
Hold
27%

Sangamo Therapeutics, Inc. Price Target

Target Price $2.04
Price $0.11
Potential
Number of Estimates 6
6 Analysts have issued a price target Sangamo Therapeutics, Inc. 2027 . The average Sangamo Therapeutics, Inc. target price is $2.04. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 8 Analysts recommend Sangamo Therapeutics, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Sangamo Therapeutics, Inc. stock has an average upside potential 2027 of . Most analysts recommend the Sangamo Therapeutics, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

7 Analysts have issued a sales forecast Sangamo Therapeutics, Inc. 2026 . The average Sangamo Therapeutics, Inc. sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $39.6m 31.57%
2026
2027
2028
2029
2030
2031
2032
2033

4 Analysts have issued an Sangamo Therapeutics, Inc. EBITDA forecast 2026. The average Sangamo Therapeutics, Inc. EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-104m 11.82%
2026
2027
2028
2029
2030
2031

EBITDA Margin

2025 -263.06% 63.42%
2026
2027
2028
2029
2030
2031

7 Sangamo Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Sangamo Therapeutics, Inc. net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-123m 25.52%
2026
2027
2028
2029
2030
2031
2032
2033

Net Margin

2025 -310.82% 83.43%
2026
2027
2028
2029
2030
2031
2032
2033

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
P/E ???

7 Analysts have issued a Sangamo Therapeutics, Inc. forecast for earnings per share. The average Sangamo Therapeutics, Inc. EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.44 10.20%
2026
2027
2028
2029
2030
2031
2032
2033

P/E ratio

Current -0.34 86.76%
2026
2027
2028
2029
2030
2031
2032
2033

Current Sangamo Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
Analyst Rating Date
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today